CSNK1A1L/CSNK1A1 Antibody

What is the functional role of CSNK1A1L/CSNK1A1 in cellular signaling pathways?

CSNK1A1L/CSNK1A1 functions as a serine/threonine kinase that plays critical roles in multiple cellular pathways. CSNK1A1L dynamically associates with the CBM complex upon T cell receptor engagement to participate in cytokine production and lymphocyte proliferation. It subsequently promotes the phosphorylation and inactivation of CARMA1, governing antigen-receptor-induced NF-kappa-B activation and human lymphoma cell survival . CSNK1A1 is also a key component of the Wnt signaling pathway, where it phosphorylates β-catenin at Ser-45, marking it for degradation when the pathway is inactive . Additionally, it may participate in chromosomal segregation during mitosis and cytoskeleton disassembly, potentially regulating epithelial cell migration .

How should I validate CSNK1A1L/CSNK1A1 antibody specificity for my experiments?

Validating antibody specificity requires a multi-step approach:

• Western blot analysis: Perform western blots using positive control cell lines known to express CSNK1A1L/CSNK1A1 alongside negative controls. Look for a single band at the expected molecular weight (approximately 38-39 kDa).

• Immunoprecipitation followed by mass spectrometry: This combination can confirm that the antibody is indeed capturing the intended protein.

• Knockdown/knockout validation: Use siRNA, shRNA, or CRISPR-Cas9 to reduce or eliminate CSNK1A1L/CSNK1A1 expression and confirm reduced antibody signal.

• Peptide competition assay: Pre-incubate the antibody with excess target peptide to verify signal suppression in subsequent applications.

• Cross-reactivity testing: Test the antibody against closely related proteins, particularly other casein kinase family members, to ensure specificity.

What are the recommended fixation methods for immunohistochemistry using CSNK1A1L/CSNK1A1 antibodies?

For optimal results in immunohistochemistry:

• Paraformaldehyde fixation: 4% PFA for 15-20 minutes at room temperature works well for most applications, preserving both antigenicity and cellular morphology.

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) may be necessary to unmask the epitope, especially in formalin-fixed, paraffin-embedded tissues.

• Blocking conditions: Use 5-10% normal serum (from the species in which the secondary antibody was raised) with 0.1-0.3% Triton X-100 for permeabilization.

• Antibody dilution optimization: Titrate the antibody to determine optimal concentration, typically starting at the manufacturer's recommended dilution and testing 2-fold dilutions in either direction.

• Incubation conditions: Overnight incubation at 4°C often yields optimal signal-to-noise ratio for CSNK1A1L/CSNK1A1 antibodies.

How can I effectively study CSNK1A1 mutations associated with hematological disorders?

Studying CSNK1A1 mutations in hematological disorders requires specialized methodologies:

• Conditional knockout models: Generate murine models with conditional inactivation of Csnk1a1 to study haploinsufficiency effects. Research has shown that Csnk1a1 haploinsufficiency induces hematopoietic stem cell expansion and provides a competitive repopulation advantage, while homozygous deletion induces hematopoietic stem cell failure .

• Sequencing approaches: Perform targeted deep sequencing of CSNK1A1 in patient samples, particularly focusing on del(5q) MDS patients to identify recurrent somatic mutations on the non-deleted allele .

• Drug sensitivity assays: Test the sensitivity of heterozygous CSNK1A1-inactivated cells to CSNK1 inhibitors compared to cells with two intact alleles. This approach leverages the finding that heterozygous inactivation sensitizes cells to CSNK1 inhibitors .

• Molecular glue degrader applications: Consider using potent and selective CK1α-targeting molecular glue degraders like dCK1α-1 and dCK1α-2 in your research, as these have shown promise in targeting CSNK1A1 with nanomolar potency .

• Downstream target analysis: Monitor changes in Rps6 phosphorylation and p53 activity, as CSNK1A1 knockdown has been shown to decrease Rps6 phosphorylation and increase p53 activity .

What are the best approaches for studying the role of CSNK1A1 in Wnt/β-catenin signaling?

To effectively study CSNK1A1's role in Wnt/β-catenin signaling:

• Co-immunoprecipitation studies: Use co-IP to assess interactions between CSNK1A1 and β-catenin under various conditions. This approach revealed that mutations in CSNK1A1 can lead to reduced interactions with β-catenin .

• β-catenin level monitoring: Measure intracellular β-catenin levels using western blotting following CSNK1A1 manipulation. Mutations or inhibition of CSNK1A1 typically result in elevated β-catenin levels due to reduced phosphorylation and subsequent degradation .

• Protein structure modeling: Use homology-modeling (e.g., SWISS-MODEL) to predict the tertiary structure of wild-type and mutated CSNK1A1. Software like PyMOL can then be used to predict the effects of specific variants, such as p.Ala216Pro and p.His200_Ile201del .

• Plasmid construction and mutagenesis: Create expression vectors containing wild-type or mutant CSNK1A1 using site-directed mutagenesis to study functional consequences of specific mutations .

• Downstream gene expression analysis: Measure the expression of Wnt/β-catenin target genes using qRT-PCR or RNA-seq following CSNK1A1 manipulation to assess pathway activation.

How can I design experiments to investigate CSNK1A1's role in neurological disorders?

To investigate CSNK1A1's role in neurological disorders:

• De novo mutation screening: Perform whole exome sequencing (WES) on patient-parent trios to identify de novo mutations in CSNK1A1, particularly in patients with infantile spasms syndrome (ISS) or other epileptic encephalopathies .

• Functional validation of mutations: Use in vitro analyses to assess the effects of identified mutations on mRNA and protein expression, as well as on protein-protein interactions .

• Cell proliferation assays: Implement EdU incorporation assays to measure cell proliferation rates in cells expressing wild-type versus mutant CSNK1A1. Research has shown that cells transfected with mutant CSNK1A1 plasmids exhibit elevated proliferation rates .

• Neuronal differentiation models: Use neuronal differentiation models (e.g., iPSC-derived neurons) to study the effects of CSNK1A1 mutations on neurogenesis and neuronal function.

• In vivo models: Consider developing zebrafish or mouse models expressing CSNK1A1 mutations to study behavioral and electrophysiological phenotypes relevant to neurological disorders.

What are the common pitfalls when using CSNK1A1L/CSNK1A1 antibodies in different applications?

Common pitfalls and their solutions include:

• Cross-reactivity with other casein kinase isoforms: CSNK1A1L/CSNK1A1 shares sequence homology with other casein kinase family members. Always validate antibody specificity using appropriate controls and consider using antibodies raised against unique regions of the protein.

• Phosphorylation-dependent epitope masking: If the antibody recognizes an epitope that can be phosphorylated, phosphorylation status may affect antibody binding. Consider using phosphatase treatment of your samples to address this issue.

• Protein degradation during sample preparation: CSNK1A1 can be susceptible to degradation. Use fresh samples, maintain cold temperatures during preparation, and include protease inhibitors in your lysis buffers.

• Cell-type specific expression patterns: Expression levels of CSNK1A1 vary across cell types. Ensure you're using appropriate positive controls specific to your experimental system.

• Antibody batch variability: Different lots of the same antibody may show variations in specificity and sensitivity. Validate each new batch against previously used batches.

How can I optimize immunoprecipitation protocols specifically for CSNK1A1L/CSNK1A1?

For optimal immunoprecipitation of CSNK1A1L/CSNK1A1:

• Lysis buffer composition: Use a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40 or Triton X-100, 1 mM EDTA, supplemented with protease and phosphatase inhibitors.

• Cross-linking considerations: For transient or weak interactions, consider using reversible cross-linking agents like DSP (dithiobis[succinimidyl propionate]) prior to cell lysis.

• Antibody coupling: For cleaner results, consider covalently coupling the antibody to beads (e.g., using dimethyl pimelimidate) to avoid antibody contamination in the eluted sample.

• Washing stringency: Balance between stringent washing to reduce background and preserving specific interactions. For CSNK1A1-β-catenin interactions, moderate washing conditions are typically optimal.

• Elution methods: For detecting CSNK1A1 interactions with β-catenin, gentle elution with low pH glycine buffer (pH 2.8) followed by immediate neutralization often yields better results than boiling in SDS sample buffer.

What control experiments should be included when studying CSNK1A1 in disease models?

Essential control experiments include:

• Genetic rescue experiments: If studying the effects of CSNK1A1 knockdown or mutation, perform rescue experiments with wild-type CSNK1A1 to confirm specificity of observed phenotypes.

• Isogenic cell line comparisons: Generate isogenic cell lines differing only in CSNK1A1 status to minimize confounding variables.

• Dose-response studies: When using inhibitors or degraders targeting CSNK1A1, perform dose-response studies to establish specificity and rule out off-target effects.

• Multiple model systems: Validate findings across multiple model systems (e.g., different cell lines, primary cells, and animal models) to ensure robustness.

• Temporal controls: For dynamic processes like Wnt signaling, include appropriate temporal controls to account for pathway dynamics.

How can I quantitatively assess CSNK1A1 kinase activity in experimental samples?

Quantitative assessment of CSNK1A1 kinase activity can be performed using:

• In vitro kinase assays: Immunoprecipitate CSNK1A1 from your samples and incubate with purified substrate (e.g., β-catenin) and ATP. Measure phosphorylation using phospho-specific antibodies or 32P-ATP incorporation.

• FRET-based biosensors: Develop or utilize existing FRET-based biosensors that change conformation upon phosphorylation by CSNK1A1, allowing real-time monitoring of kinase activity in live cells.

• Mass spectrometry-based approaches: Use quantitative phosphoproteomics to measure changes in the phosphorylation status of known CSNK1A1 substrates following experimental manipulation.

• Cellular reporter systems: Establish reporter systems based on the stability or localization of β-catenin, which is directly regulated by CSNK1A1-mediated phosphorylation.

• Bioluminescence resonance energy transfer (BRET): Implement BRET assays to monitor CSNK1A1-substrate interactions in real-time.

What advanced techniques can be used to study the structural changes in mutant CSNK1A1 proteins?

Advanced structural analysis techniques include:

• Molecular dynamics simulations: Conduct molecular dynamics simulations to study how mutations affect protein flexibility, substrate binding, and catalytic activity over time.

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS): Use HDX-MS to examine conformational changes and dynamics of wild-type versus mutant CSNK1A1 proteins.

• X-ray crystallography or cryo-EM: Determine high-resolution structures of wild-type and mutant CSNK1A1 proteins, ideally in complex with substrates or binding partners.

• Nuclear magnetic resonance (NMR) spectroscopy: Apply NMR to study the solution structure and dynamics of CSNK1A1 and how mutations affect these properties.

• Thermal shift assays: Use differential scanning fluorimetry to assess protein stability changes induced by mutations or ligand binding.

How can I develop and validate cellular models to study the effects of CSNK1A1 molecular glue degraders?

To develop and validate cellular models for studying CSNK1A1 degraders:

• Reporter cell line generation: Create cell lines expressing CSNK1A1 fused to a reporter protein (e.g., HiBiT or NanoLuc) to enable real-time monitoring of degradation kinetics .

• Degradation parameter quantification: Establish robust quantification methods for determining DC50 (concentration causing 50% degradation) and Dmax (maximum degradation) values, as shown in the following table from the research on CK1α degraders :

• Ternary complex formation assays: Implement NanoBiT assays to confirm and quantify ternary complex formation between CRBN (the E3 ligase receptor), the degrader molecule, and CSNK1A1 .

• Selectivity profiling: Develop parallel cell lines expressing related kinases to assess the selectivity of your degraders across the kinome.

• Functional readouts: Establish downstream functional readouts, such as β-catenin levels, Wnt pathway activation, or cell proliferation, to connect degradation efficiency with biological outcomes.

What are the latest research developments regarding CSNK1A1 as a therapeutic target in hematological malignancies?

Recent research developments include:

• Molecular glue degraders: Development of potent and selective CK1α-targeting molecular glue degraders like dCK1α-1, which can degrade CK1α with single-digit nanomolar potency. Furthermore, orally bioavailable derivatives like dCK1α-2 have been developed, showing robust efficacy in degrading CK1α and exhibiting excellent compatibility in xenograft mouse models .

• Selective targeting in leukemia: Studies have shown that CSNK1A1 inhibition using compounds like D4476 (a casein kinase 1 inhibitor) exhibits selective killing of leukemia stem cells (LSCs) over normal hematopoietic stem and progenitor cells (HSPCs) .

• Mechanistic insights: CSNK1A1 inhibition has been shown to cause reduced Rps6 phosphorylation and activation of p53, resulting in selective elimination of leukemia cells. Notably, p53-null leukemias were found to be insensitive to Csnk1a1 knockdown .

• Del(5q) MDS targeting: CSNK1A1 has emerged as a central player in the biology of del(5q) MDS and a promising therapeutic target. Heterozygous inactivation of CSNK1A1 sensitizes cells to CSNK1 inhibitors relative to cells with two intact alleles .

• Combination therapies: Emerging research is exploring combination approaches targeting CSNK1A1 alongside other pathways dysregulated in hematological malignancies.

How is CSNK1A1 being investigated in the context of neurological disorders?

CSNK1A1's role in neurological disorders is being investigated through:

• De novo mutation identification: Recent research has identified two de novo mutations in the CSNK1A1 gene (c.646G > C/p.Ala216Pro and c.599_604delACATAC/p.His200_Ile201del) in patients with infantile spasms syndrome (ISS) .

• Molecular mechanism elucidation: Studies have shown that these mutations lead to reduced interactions between CSNK1A1 and β-catenin, resulting in excessive intracellular β-catenin and aberrant expression of downstream genes .

• Wnt/β-catenin signaling focus: Research has highlighted the importance of the Wnt/β-catenin signaling pathway, which is crucial to neurogenesis, in the pathogenesis of ISS. An abnormal rise in β-catenin level has been utilized to generate genetic models for ISS .

• Cellular proliferation effects: Research has shown that cells transfected with mutant CSNK1A1 plasmids exhibit elevated EdU positive rates compared to wild-type, suggesting altered cellular proliferation dynamics .

• Structural insights: Protein structure modeling has revealed that mutations in the kinase domain of CSNK1A1 can affect the polar interactions between β-catenin and CSNK1A1, which are critical for effective phosphorylation at Ser45 .

What are the most promising strategies for developing selective CSNK1A1 inhibitors or degraders?

Promising strategies include:

• Structure-guided design: Leveraging crystallographic or cryo-EM structures of CSNK1A1 to design highly selective inhibitors targeting unique structural features of this kinase.

• Molecular glue approach: Further refinement of molecular glue degraders like dCK1α-1 and dCK1α-2, which have shown promise in selectively targeting CSNK1A1 with nanomolar potency. The table from result shows various structural modifications and their impact on inhibitory and degradation potency:

• Allosteric targeting: Development of inhibitors targeting allosteric sites specific to CSNK1A1, potentially offering greater selectivity over ATP-competitive inhibitors.

• Substrate-competitive approaches: Design of peptide-mimetic or small molecule inhibitors that compete with specific CSNK1A1 substrates rather than ATP.

• Targeted protein degradation: Beyond molecular glue degraders, other targeted protein degradation approaches like PROTACs (Proteolysis Targeting Chimeras) are being explored for their potential to achieve higher selectivity and efficacy in targeting CSNK1A1.